201 related articles for article (PubMed ID: 10491499)
1. Global improvement of systemic scleroderma under long-term administration of octreotide.
Descamps V; Duval X; Crickx B; Bouscarat F; Coffin B; Belaich S
Eur J Dermatol; 1999 Sep; 9(6):446-8. PubMed ID: 10491499
[TBL] [Abstract][Full Text] [Related]
2. [Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin].
Lecomte T; Cavicchi M; Delchier JC
Gastroenterol Clin Biol; 2000 Mar; 24(3):361-3. PubMed ID: 10804347
[TBL] [Abstract][Full Text] [Related]
3. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
Soudah HC; Hasler WL; Owyang C
N Engl J Med; 1991 Nov; 325(21):1461-7. PubMed ID: 1944424
[TBL] [Abstract][Full Text] [Related]
4. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
[TBL] [Abstract][Full Text] [Related]
5. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
[TBL] [Abstract][Full Text] [Related]
6. Octreotide therapy in dumping syndrome: Analysis of long-term results.
Didden P; Penning C; Masclee AA
Aliment Pharmacol Ther; 2006 Nov; 24(9):1367-75. PubMed ID: 17059518
[TBL] [Abstract][Full Text] [Related]
7. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
Spahr L; Giostra E; Frossard JL; Morard I; Mentha G; Hadengue A
Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
[TBL] [Abstract][Full Text] [Related]
8. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia.
Scaglione G; Pietrini L; Russo F; Franco MR; Sorrentini I
Aliment Pharmacol Ther; 2007 Sep; 26(6):935-42. PubMed ID: 17767478
[TBL] [Abstract][Full Text] [Related]
9. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride.
Boeckxstaens GE; Bartelsman JF; Lauwers L; Tytgat GN
Am J Gastroenterol; 2002 Jan; 97(1):194-7. PubMed ID: 11811166
[TBL] [Abstract][Full Text] [Related]
10. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
[TBL] [Abstract][Full Text] [Related]
11. [Digestive manifestations in systemic sclerosis].
Attar A
Ann Med Interne (Paris); 2002 Jun; 153(4):260-4. PubMed ID: 12218892
[TBL] [Abstract][Full Text] [Related]
12. [Madecassol treatment of systemic and localized scleroderma].
Guseva NG; Starovoĭtova MN; Mach ES
Ter Arkh; 1998; 70(5):58-61. PubMed ID: 9644746
[TBL] [Abstract][Full Text] [Related]
13. [Experience in treating acromegalic patients with long-acting octreotide].
Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
[TBL] [Abstract][Full Text] [Related]
14. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.
Calguneri M; Apras S; Ozbalkan Z; Ertenli I; Kiraz S; Ozturk MA; Celik I
Clin Rheumatol; 2003 Oct; 22(4-5):289-94. PubMed ID: 14579158
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
[TBL] [Abstract][Full Text] [Related]
18. [Five cases of systemic sclerosis with associated with intestinal pseudo-obstruction].
Ishikawa M; Okada J; Kondo H
Ryumachi; 1999 Oct; 39(5):768-73. PubMed ID: 10614172
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
20. Intestinal perforation associated with octreotide therapy in scleroderma.
Malcolm A; Ellard K
Am J Gastroenterol; 2001 Nov; 96(11):3206-8. PubMed ID: 11721779
[No Abstract] [Full Text] [Related]
[Next] [New Search]
